ArticleCancer chemotherapy and pharmacology2021

Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma.

Chiung-Chi Cheng et al.PubMed ↗Publisher ↗

No numbers read from the abstract.